Kytril

Granisetron, the active ingredient in Kytril, is a 5-HT3 receptor antagonist presented as an injectable solution for intravenous use. It treats chemotherapy‑induced nausea and vomiting and postoperative nausea and vomiting in patients receiving cancer therapy or surgery, acting by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant centres and pharmacies worldwide.

Kytril (granisetron) is used to prevent and treat nausea and vomiting mediated by serotonin activation in the gastrointestinal tract and chemoreceptor trigger zone. - Chemotherapy‑induced nausea and vomiting: reduces acute and delayed nausea and vomiting in patients receiving emetogenic chemotherapy. - Postoperative nausea and vomiting: prevents nausea and vomiting after surgical procedures. - Radiation‑induced nausea and vomiting: helps control nausea and vomiting associated with radiotherapy in cancer patients.

Kytril may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported after administration. - Constipation: reduced bowel motility leading to hard stools. - Dizziness: transient sensation of light‑headedness. - Injection site reactions: erythema, pain, or swelling at the IV site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - QT prolongation or arrhythmia: cardiac rhythm disturbances that can be life‑threatening. - Severe constipation or intestinal obstruction: may require medical intervention. - Serotonin syndrome: rare but potentially fatal condition when combined with other serotonergic agents. - Hypotension: sudden drop in blood pressure, especially in susceptible patients.

When using Kytril, certain precautions should be observed to ensure patient safety. - Cardiac risk assessment: evaluate QT interval before administration, especially in patients with known cardiac disease. - Hypersensitivity monitoring: watch for signs of allergic reaction during and after infusion. - Hepatic impairment: use with caution in patients with liver dysfunction, as clearance may be reduced. - Concomitant QT‑prolonging drugs: avoid or closely monitor when used with other agents that can extend the QT interval. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Kytril can interact with other medications, influencing its safety and effectiveness.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: additive antiemetic effect may increase risk of cardiac arrhythmia. - QT‑prolonging agents (e.g., quinidine, erythromycin, haloperidol): combined use can precipitate torsades de pointes.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase granisetron plasma concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce granisetron effectiveness. - Anticholinergic drugs: may enhance constipation risk. - Other serotonergic agents: monitor for signs of serotonin syndrome.